nodes	percent_of_prediction	percent_of_DWPC	metapath
Valaciclovir—SLC10A2—Recycling of bile acids and salts—RXRA—thyroid cancer	0.0162	0.127	CbGpPWpGaD
Valaciclovir—SLC10A2—Bile acid and bile salt metabolism—RXRA—thyroid cancer	0.00848	0.0662	CbGpPWpGaD
Valaciclovir—SLC6A14—Imatinib Resistance in Chronic Myeloid Leukemia—EPO—thyroid cancer	0.00756	0.059	CbGpPWpGaD
Valaciclovir—SLC6A14—Amino acid and oligopeptide SLC transporters—SLC5A5—thyroid cancer	0.00721	0.0563	CbGpPWpGaD
Valaciclovir—SLC6A14—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00558	0.0435	CbGpPWpGaD
Valaciclovir—SLC6A14—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—thyroid cancer	0.00425	0.0331	CbGpPWpGaD
Valaciclovir—Insomnia—Vandetanib—thyroid cancer	0.00402	0.00462	CcSEcCtD
Valaciclovir—Paraesthesia—Vandetanib—thyroid cancer	0.004	0.00458	CcSEcCtD
Valaciclovir—Erythema multiforme—Sorafenib—thyroid cancer	0.00399	0.00458	CcSEcCtD
Valaciclovir—Dyspnoea—Vandetanib—thyroid cancer	0.00397	0.00455	CcSEcCtD
Valaciclovir—Dyspepsia—Vandetanib—thyroid cancer	0.00392	0.00449	CcSEcCtD
Valaciclovir—Decreased appetite—Vandetanib—thyroid cancer	0.00387	0.00444	CcSEcCtD
Valaciclovir—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00384	0.00441	CcSEcCtD
Valaciclovir—Fatigue—Vandetanib—thyroid cancer	0.00384	0.0044	CcSEcCtD
Valaciclovir—Immune system disorder—Sorafenib—thyroid cancer	0.00382	0.00438	CcSEcCtD
Valaciclovir—Mediastinal disorder—Sorafenib—thyroid cancer	0.00381	0.00437	CcSEcCtD
Valaciclovir—Constipation—Vandetanib—thyroid cancer	0.0038	0.00436	CcSEcCtD
Valaciclovir—Pain—Vandetanib—thyroid cancer	0.0038	0.00436	CcSEcCtD
Valaciclovir—Alopecia—Sorafenib—thyroid cancer	0.00373	0.00428	CcSEcCtD
Valaciclovir—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00364	0.00417	CcSEcCtD
Valaciclovir—SLC10A2—Orphan transporters—RXRA—thyroid cancer	0.00363	0.0283	CbGpPWpGaD
Valaciclovir—Body temperature increased—Vandetanib—thyroid cancer	0.00352	0.00403	CcSEcCtD
Valaciclovir—Abdominal pain—Vandetanib—thyroid cancer	0.00352	0.00403	CcSEcCtD
Valaciclovir—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC5A5—thyroid cancer	0.00341	0.0266	CbGpPWpGaD
Valaciclovir—Anaemia—Sorafenib—thyroid cancer	0.0034	0.0039	CcSEcCtD
Valaciclovir—Cough increased—Epirubicin—thyroid cancer	0.0034	0.00389	CcSEcCtD
Valaciclovir—Herpes simplex—Epirubicin—thyroid cancer	0.00337	0.00387	CcSEcCtD
Valaciclovir—Angioedema—Sorafenib—thyroid cancer	0.00336	0.00385	CcSEcCtD
Valaciclovir—Leukopenia—Sorafenib—thyroid cancer	0.00329	0.00378	CcSEcCtD
Valaciclovir—Dysarthria—Epirubicin—thyroid cancer	0.00329	0.00377	CcSEcCtD
Valaciclovir—Creatinine increased—Epirubicin—thyroid cancer	0.00327	0.00375	CcSEcCtD
Valaciclovir—Cough—Sorafenib—thyroid cancer	0.00321	0.00368	CcSEcCtD
Valaciclovir—Asthenia—Vandetanib—thyroid cancer	0.00319	0.00366	CcSEcCtD
Valaciclovir—Hypertension—Sorafenib—thyroid cancer	0.00317	0.00364	CcSEcCtD
Valaciclovir—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC5A5—thyroid cancer	0.00317	0.0247	CbGpPWpGaD
Valaciclovir—Pruritus—Vandetanib—thyroid cancer	0.00315	0.00361	CcSEcCtD
Valaciclovir—Cough increased—Doxorubicin—thyroid cancer	0.00314	0.0036	CcSEcCtD
Valaciclovir—Arthralgia—Sorafenib—thyroid cancer	0.00313	0.00359	CcSEcCtD
Valaciclovir—Myalgia—Sorafenib—thyroid cancer	0.00313	0.00359	CcSEcCtD
Valaciclovir—Herpes simplex—Doxorubicin—thyroid cancer	0.00312	0.00358	CcSEcCtD
Valaciclovir—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00311	0.00357	CcSEcCtD
Valaciclovir—Phosphatase alkaline increased—Epirubicin—thyroid cancer	0.00311	0.00357	CcSEcCtD
Valaciclovir—Dry mouth—Sorafenib—thyroid cancer	0.00306	0.00351	CcSEcCtD
Valaciclovir—Diarrhoea—Vandetanib—thyroid cancer	0.00304	0.00349	CcSEcCtD
Valaciclovir—Dysarthria—Doxorubicin—thyroid cancer	0.00304	0.00349	CcSEcCtD
Valaciclovir—Creatinine increased—Doxorubicin—thyroid cancer	0.00302	0.00347	CcSEcCtD
Valaciclovir—SLC6A14—NRF2 pathway—SLC5A5—thyroid cancer	0.00301	0.0235	CbGpPWpGaD
Valaciclovir—Anaphylactic shock—Sorafenib—thyroid cancer	0.003	0.00344	CcSEcCtD
Valaciclovir—Infection—Sorafenib—thyroid cancer	0.00298	0.00342	CcSEcCtD
Valaciclovir—Nervous system disorder—Sorafenib—thyroid cancer	0.00294	0.00338	CcSEcCtD
Valaciclovir—Dizziness—Vandetanib—thyroid cancer	0.00294	0.00337	CcSEcCtD
Valaciclovir—Thrombocytopenia—Sorafenib—thyroid cancer	0.00294	0.00337	CcSEcCtD
Valaciclovir—Aplastic anaemia—Epirubicin—thyroid cancer	0.00292	0.00335	CcSEcCtD
Valaciclovir—Skin disorder—Sorafenib—thyroid cancer	0.00292	0.00334	CcSEcCtD
Valaciclovir—Phosphatase alkaline increased—Doxorubicin—thyroid cancer	0.00288	0.0033	CcSEcCtD
Valaciclovir—Anorexia—Sorafenib—thyroid cancer	0.00286	0.00328	CcSEcCtD
Valaciclovir—Coma—Epirubicin—thyroid cancer	0.00284	0.00326	CcSEcCtD
Valaciclovir—Vomiting—Vandetanib—thyroid cancer	0.00283	0.00324	CcSEcCtD
Valaciclovir—Mouth ulceration—Epirubicin—thyroid cancer	0.00281	0.00322	CcSEcCtD
Valaciclovir—Rash—Vandetanib—thyroid cancer	0.00281	0.00322	CcSEcCtD
Valaciclovir—Dermatitis—Vandetanib—thyroid cancer	0.0028	0.00321	CcSEcCtD
Valaciclovir—Headache—Vandetanib—thyroid cancer	0.00279	0.0032	CcSEcCtD
Valaciclovir—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00273	0.00314	CcSEcCtD
Valaciclovir—Aplastic anaemia—Doxorubicin—thyroid cancer	0.0027	0.0031	CcSEcCtD
Valaciclovir—Dyspnoea—Sorafenib—thyroid cancer	0.00268	0.00307	CcSEcCtD
Valaciclovir—Nausea—Vandetanib—thyroid cancer	0.00264	0.00303	CcSEcCtD
Valaciclovir—Dyspepsia—Sorafenib—thyroid cancer	0.00264	0.00303	CcSEcCtD
Valaciclovir—Coma—Doxorubicin—thyroid cancer	0.00263	0.00301	CcSEcCtD
Valaciclovir—Decreased appetite—Sorafenib—thyroid cancer	0.00261	0.00299	CcSEcCtD
Valaciclovir—Mouth ulceration—Doxorubicin—thyroid cancer	0.0026	0.00298	CcSEcCtD
Valaciclovir—Blood alkaline phosphatase increased—Epirubicin—thyroid cancer	0.00259	0.00298	CcSEcCtD
Valaciclovir—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00259	0.00297	CcSEcCtD
Valaciclovir—Fatigue—Sorafenib—thyroid cancer	0.00259	0.00297	CcSEcCtD
Valaciclovir—SLC10A2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00258	0.0201	CbGpPWpGaD
Valaciclovir—Photosensitivity—Epirubicin—thyroid cancer	0.00257	0.00295	CcSEcCtD
Valaciclovir—Pain—Sorafenib—thyroid cancer	0.00257	0.00294	CcSEcCtD
Valaciclovir—Constipation—Sorafenib—thyroid cancer	0.00257	0.00294	CcSEcCtD
Valaciclovir—SLC6A14—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00253	0.0198	CbGpPWpGaD
Valaciclovir—SLC6A14—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00253	0.0198	CbGpPWpGaD
Valaciclovir—SLC6A14—NRF2 pathway—RXRA—thyroid cancer	0.00253	0.0197	CbGpPWpGaD
Valaciclovir—Eczema—Epirubicin—thyroid cancer	0.00251	0.00288	CcSEcCtD
Valaciclovir—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00245	0.00281	CcSEcCtD
Valaciclovir—Renal failure acute—Epirubicin—thyroid cancer	0.00244	0.0028	CcSEcCtD
Valaciclovir—Blood alkaline phosphatase increased—Doxorubicin—thyroid cancer	0.0024	0.00275	CcSEcCtD
Valaciclovir—Urticaria—Sorafenib—thyroid cancer	0.00238	0.00273	CcSEcCtD
Valaciclovir—Photosensitivity—Doxorubicin—thyroid cancer	0.00238	0.00273	CcSEcCtD
Valaciclovir—Abdominal pain—Sorafenib—thyroid cancer	0.00237	0.00272	CcSEcCtD
Valaciclovir—Body temperature increased—Sorafenib—thyroid cancer	0.00237	0.00272	CcSEcCtD
Valaciclovir—Renal impairment—Epirubicin—thyroid cancer	0.00237	0.00272	CcSEcCtD
Valaciclovir—Eczema—Doxorubicin—thyroid cancer	0.00232	0.00266	CcSEcCtD
Valaciclovir—Renal failure acute—Doxorubicin—thyroid cancer	0.00226	0.00259	CcSEcCtD
Valaciclovir—Osteoarthritis—Epirubicin—thyroid cancer	0.00226	0.00259	CcSEcCtD
Valaciclovir—Migraine—Epirubicin—thyroid cancer	0.00222	0.00255	CcSEcCtD
Valaciclovir—Hypersensitivity—Sorafenib—thyroid cancer	0.00221	0.00254	CcSEcCtD
Valaciclovir—Renal impairment—Doxorubicin—thyroid cancer	0.00219	0.00252	CcSEcCtD
Valaciclovir—SLC6A14—NRF2 pathway—NRG1—thyroid cancer	0.00219	0.0171	CbGpPWpGaD
Valaciclovir—Face oedema—Epirubicin—thyroid cancer	0.00218	0.0025	CcSEcCtD
Valaciclovir—SLC22A8—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00218	0.017	CbGpPWpGaD
Valaciclovir—Asthenia—Sorafenib—thyroid cancer	0.00215	0.00247	CcSEcCtD
Valaciclovir—Pruritus—Sorafenib—thyroid cancer	0.00212	0.00244	CcSEcCtD
Valaciclovir—Ataxia—Epirubicin—thyroid cancer	0.00212	0.00243	CcSEcCtD
Valaciclovir—Blood creatinine increased—Epirubicin—thyroid cancer	0.00211	0.00242	CcSEcCtD
Valaciclovir—Dehydration—Epirubicin—thyroid cancer	0.0021	0.00241	CcSEcCtD
Valaciclovir—Osteoarthritis—Doxorubicin—thyroid cancer	0.00209	0.00239	CcSEcCtD
Valaciclovir—Liver function test abnormal—Epirubicin—thyroid cancer	0.00208	0.00239	CcSEcCtD
Valaciclovir—Migraine—Doxorubicin—thyroid cancer	0.00206	0.00236	CcSEcCtD
Valaciclovir—Diarrhoea—Sorafenib—thyroid cancer	0.00205	0.00236	CcSEcCtD
Valaciclovir—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.00203	0.00233	CcSEcCtD
Valaciclovir—Nasopharyngitis—Epirubicin—thyroid cancer	0.00202	0.00231	CcSEcCtD
Valaciclovir—Face oedema—Doxorubicin—thyroid cancer	0.00202	0.00231	CcSEcCtD
Valaciclovir—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—thyroid cancer	0.00201	0.0157	CbGpPWpGaD
Valaciclovir—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.00199	0.00228	CcSEcCtD
Valaciclovir—Dizziness—Sorafenib—thyroid cancer	0.00198	0.00228	CcSEcCtD
Valaciclovir—Ataxia—Doxorubicin—thyroid cancer	0.00196	0.00225	CcSEcCtD
Valaciclovir—Blood creatinine increased—Doxorubicin—thyroid cancer	0.00196	0.00224	CcSEcCtD
Valaciclovir—Influenza—Epirubicin—thyroid cancer	0.00195	0.00224	CcSEcCtD
Valaciclovir—Dehydration—Doxorubicin—thyroid cancer	0.00194	0.00223	CcSEcCtD
Valaciclovir—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00193	0.00221	CcSEcCtD
Valaciclovir—Vomiting—Sorafenib—thyroid cancer	0.00191	0.00219	CcSEcCtD
Valaciclovir—SLC6A14—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.0019	0.0148	CbGpPWpGaD
Valaciclovir—Rash—Sorafenib—thyroid cancer	0.00189	0.00217	CcSEcCtD
Valaciclovir—Dermatitis—Sorafenib—thyroid cancer	0.00189	0.00217	CcSEcCtD
Valaciclovir—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00188	0.00216	CcSEcCtD
Valaciclovir—Headache—Sorafenib—thyroid cancer	0.00188	0.00216	CcSEcCtD
Valaciclovir—Bronchitis—Epirubicin—thyroid cancer	0.00188	0.00215	CcSEcCtD
Valaciclovir—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00187	0.00214	CcSEcCtD
Valaciclovir—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—thyroid cancer	0.00186	0.0146	CbGpPWpGaD
Valaciclovir—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.00184	0.00211	CcSEcCtD
Valaciclovir—SLC22A6—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—CP—thyroid cancer	0.00182	0.0142	CbGpPWpGaD
Valaciclovir—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.00181	0.00208	CcSEcCtD
Valaciclovir—Influenza—Doxorubicin—thyroid cancer	0.0018	0.00207	CcSEcCtD
Valaciclovir—Nausea—Sorafenib—thyroid cancer	0.00178	0.00204	CcSEcCtD
Valaciclovir—SLC10A2—Metabolism—MINPP1—thyroid cancer	0.00178	0.0139	CbGpPWpGaD
Valaciclovir—Photosensitivity reaction—Epirubicin—thyroid cancer	0.00178	0.00204	CcSEcCtD
Valaciclovir—Bronchitis—Doxorubicin—thyroid cancer	0.00174	0.00199	CcSEcCtD
Valaciclovir—Renal failure—Epirubicin—thyroid cancer	0.00171	0.00196	CcSEcCtD
Valaciclovir—Stomatitis—Epirubicin—thyroid cancer	0.0017	0.00194	CcSEcCtD
Valaciclovir—Urinary tract infection—Epirubicin—thyroid cancer	0.00169	0.00194	CcSEcCtD
Valaciclovir—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00168	0.00192	CcSEcCtD
Valaciclovir—Haematuria—Epirubicin—thyroid cancer	0.00166	0.0019	CcSEcCtD
Valaciclovir—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.00165	0.00189	CcSEcCtD
Valaciclovir—Hepatobiliary disease—Epirubicin—thyroid cancer	0.00164	0.00189	CcSEcCtD
Valaciclovir—Sinusitis—Epirubicin—thyroid cancer	0.00163	0.00187	CcSEcCtD
Valaciclovir—Renal failure—Doxorubicin—thyroid cancer	0.00158	0.00181	CcSEcCtD
Valaciclovir—Stomatitis—Doxorubicin—thyroid cancer	0.00157	0.0018	CcSEcCtD
Valaciclovir—Rhinitis—Epirubicin—thyroid cancer	0.00157	0.0018	CcSEcCtD
Valaciclovir—Urinary tract infection—Doxorubicin—thyroid cancer	0.00156	0.00179	CcSEcCtD
Valaciclovir—Hepatitis—Epirubicin—thyroid cancer	0.00156	0.00179	CcSEcCtD
Valaciclovir—Pharyngitis—Epirubicin—thyroid cancer	0.00155	0.00178	CcSEcCtD
Valaciclovir—Urinary tract disorder—Epirubicin—thyroid cancer	0.00154	0.00177	CcSEcCtD
Valaciclovir—Oedema peripheral—Epirubicin—thyroid cancer	0.00154	0.00176	CcSEcCtD
Valaciclovir—Haematuria—Doxorubicin—thyroid cancer	0.00153	0.00176	CcSEcCtD
Valaciclovir—Urethral disorder—Epirubicin—thyroid cancer	0.00153	0.00176	CcSEcCtD
Valaciclovir—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00152	0.00175	CcSEcCtD
Valaciclovir—SLC10A2—Metabolism—NDUFA13—thyroid cancer	0.00152	0.0118	CbGpPWpGaD
Valaciclovir—Sinusitis—Doxorubicin—thyroid cancer	0.00151	0.00173	CcSEcCtD
Valaciclovir—Erythema multiforme—Epirubicin—thyroid cancer	0.00148	0.00169	CcSEcCtD
Valaciclovir—Rhinitis—Doxorubicin—thyroid cancer	0.00145	0.00166	CcSEcCtD
Valaciclovir—Hepatitis—Doxorubicin—thyroid cancer	0.00144	0.00166	CcSEcCtD
Valaciclovir—Pharyngitis—Doxorubicin—thyroid cancer	0.00143	0.00164	CcSEcCtD
Valaciclovir—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00143	0.00164	CcSEcCtD
Valaciclovir—SLC10A2—Metabolism—CHST14—thyroid cancer	0.00142	0.0111	CbGpPWpGaD
Valaciclovir—Oedema peripheral—Doxorubicin—thyroid cancer	0.00142	0.00163	CcSEcCtD
Valaciclovir—Urethral disorder—Doxorubicin—thyroid cancer	0.00142	0.00162	CcSEcCtD
Valaciclovir—Immune system disorder—Epirubicin—thyroid cancer	0.00141	0.00162	CcSEcCtD
Valaciclovir—SLC10A2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00141	0.011	CbGpPWpGaD
Valaciclovir—SLC10A2—Transmembrane transport of small molecules—CP—thyroid cancer	0.00141	0.011	CbGpPWpGaD
Valaciclovir—Mediastinal disorder—Epirubicin—thyroid cancer	0.00141	0.00161	CcSEcCtD
Valaciclovir—Chills—Epirubicin—thyroid cancer	0.0014	0.00161	CcSEcCtD
Valaciclovir—SLC10A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00139	0.0108	CbGpPWpGaD
Valaciclovir—Alopecia—Epirubicin—thyroid cancer	0.00138	0.00158	CcSEcCtD
Valaciclovir—Erythema multiforme—Doxorubicin—thyroid cancer	0.00137	0.00157	CcSEcCtD
Valaciclovir—Flatulence—Epirubicin—thyroid cancer	0.00134	0.00154	CcSEcCtD
Valaciclovir—Tension—Epirubicin—thyroid cancer	0.00133	0.00153	CcSEcCtD
Valaciclovir—Nervousness—Epirubicin—thyroid cancer	0.00132	0.00151	CcSEcCtD
Valaciclovir—Back pain—Epirubicin—thyroid cancer	0.00131	0.00151	CcSEcCtD
Valaciclovir—Immune system disorder—Doxorubicin—thyroid cancer	0.0013	0.0015	CcSEcCtD
Valaciclovir—Mediastinal disorder—Doxorubicin—thyroid cancer	0.0013	0.00149	CcSEcCtD
Valaciclovir—Chills—Doxorubicin—thyroid cancer	0.0013	0.00149	CcSEcCtD
Valaciclovir—SLC6A14—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00129	0.0101	CbGpPWpGaD
Valaciclovir—SLC6A14—Transmembrane transport of small molecules—CP—thyroid cancer	0.00129	0.0101	CbGpPWpGaD
Valaciclovir—Alopecia—Doxorubicin—thyroid cancer	0.00128	0.00146	CcSEcCtD
Valaciclovir—SLC6A14—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.00127	0.00989	CbGpPWpGaD
Valaciclovir—Anaemia—Epirubicin—thyroid cancer	0.00126	0.00144	CcSEcCtD
Valaciclovir—Agitation—Epirubicin—thyroid cancer	0.00125	0.00143	CcSEcCtD
Valaciclovir—Flatulence—Doxorubicin—thyroid cancer	0.00124	0.00142	CcSEcCtD
Valaciclovir—Tension—Doxorubicin—thyroid cancer	0.00123	0.00142	CcSEcCtD
Valaciclovir—Nervousness—Doxorubicin—thyroid cancer	0.00122	0.0014	CcSEcCtD
Valaciclovir—Leukopenia—Epirubicin—thyroid cancer	0.00122	0.0014	CcSEcCtD
Valaciclovir—Back pain—Doxorubicin—thyroid cancer	0.00122	0.0014	CcSEcCtD
Valaciclovir—SLC15A2—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.0012	0.00936	CbGpPWpGaD
Valaciclovir—SLC15A2—SLC-mediated transmembrane transport—CP—thyroid cancer	0.0012	0.00936	CbGpPWpGaD
Valaciclovir—Cough—Epirubicin—thyroid cancer	0.00119	0.00136	CcSEcCtD
Valaciclovir—Convulsion—Epirubicin—thyroid cancer	0.00118	0.00135	CcSEcCtD
Valaciclovir—Hypertension—Epirubicin—thyroid cancer	0.00117	0.00135	CcSEcCtD
Valaciclovir—Anaemia—Doxorubicin—thyroid cancer	0.00116	0.00133	CcSEcCtD
Valaciclovir—Arthralgia—Epirubicin—thyroid cancer	0.00116	0.00133	CcSEcCtD
Valaciclovir—Chest pain—Epirubicin—thyroid cancer	0.00116	0.00133	CcSEcCtD
Valaciclovir—Myalgia—Epirubicin—thyroid cancer	0.00116	0.00133	CcSEcCtD
Valaciclovir—Agitation—Doxorubicin—thyroid cancer	0.00116	0.00133	CcSEcCtD
Valaciclovir—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00115	0.00132	CcSEcCtD
Valaciclovir—SLC10A2—Metabolism—HPGD—thyroid cancer	0.00115	0.00897	CbGpPWpGaD
Valaciclovir—Dry mouth—Epirubicin—thyroid cancer	0.00113	0.0013	CcSEcCtD
Valaciclovir—Leukopenia—Doxorubicin—thyroid cancer	0.00113	0.00129	CcSEcCtD
Valaciclovir—Confusional state—Epirubicin—thyroid cancer	0.00112	0.00128	CcSEcCtD
Valaciclovir—SLC15A1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00111	0.00869	CbGpPWpGaD
Valaciclovir—SLC15A1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00111	0.00869	CbGpPWpGaD
Valaciclovir—Oedema—Epirubicin—thyroid cancer	0.00111	0.00127	CcSEcCtD
Valaciclovir—Anaphylactic shock—Epirubicin—thyroid cancer	0.00111	0.00127	CcSEcCtD
Valaciclovir—Infection—Epirubicin—thyroid cancer	0.0011	0.00126	CcSEcCtD
Valaciclovir—Cough—Doxorubicin—thyroid cancer	0.0011	0.00126	CcSEcCtD
Valaciclovir—Convulsion—Doxorubicin—thyroid cancer	0.00109	0.00125	CcSEcCtD
Valaciclovir—Nervous system disorder—Epirubicin—thyroid cancer	0.00109	0.00125	CcSEcCtD
Valaciclovir—Thrombocytopenia—Epirubicin—thyroid cancer	0.00109	0.00125	CcSEcCtD
Valaciclovir—Hypertension—Doxorubicin—thyroid cancer	0.00109	0.00125	CcSEcCtD
Valaciclovir—Tachycardia—Epirubicin—thyroid cancer	0.00108	0.00124	CcSEcCtD
Valaciclovir—Skin disorder—Epirubicin—thyroid cancer	0.00108	0.00124	CcSEcCtD
Valaciclovir—Myalgia—Doxorubicin—thyroid cancer	0.00107	0.00123	CcSEcCtD
Valaciclovir—Chest pain—Doxorubicin—thyroid cancer	0.00107	0.00123	CcSEcCtD
Valaciclovir—Arthralgia—Doxorubicin—thyroid cancer	0.00107	0.00123	CcSEcCtD
Valaciclovir—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00106	0.00122	CcSEcCtD
Valaciclovir—Anorexia—Epirubicin—thyroid cancer	0.00106	0.00121	CcSEcCtD
Valaciclovir—SLC10A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.00105	0.00823	CbGpPWpGaD
Valaciclovir—Dry mouth—Doxorubicin—thyroid cancer	0.00105	0.0012	CcSEcCtD
Valaciclovir—Confusional state—Doxorubicin—thyroid cancer	0.00103	0.00119	CcSEcCtD
Valaciclovir—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00103	0.00118	CcSEcCtD
Valaciclovir—Oedema—Doxorubicin—thyroid cancer	0.00103	0.00118	CcSEcCtD
Valaciclovir—Infection—Doxorubicin—thyroid cancer	0.00102	0.00117	CcSEcCtD
Valaciclovir—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.00101	0.00116	CcSEcCtD
Valaciclovir—Nervous system disorder—Doxorubicin—thyroid cancer	0.00101	0.00115	CcSEcCtD
Valaciclovir—Thrombocytopenia—Doxorubicin—thyroid cancer	0.001	0.00115	CcSEcCtD
Valaciclovir—Insomnia—Epirubicin—thyroid cancer	0.001	0.00115	CcSEcCtD
Valaciclovir—Tachycardia—Doxorubicin—thyroid cancer	0.001	0.00115	CcSEcCtD
Valaciclovir—Skin disorder—Doxorubicin—thyroid cancer	0.000997	0.00114	CcSEcCtD
Valaciclovir—Paraesthesia—Epirubicin—thyroid cancer	0.000996	0.00114	CcSEcCtD
Valaciclovir—SLC22A8—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00099	0.00773	CbGpPWpGaD
Valaciclovir—SLC22A8—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00099	0.00773	CbGpPWpGaD
Valaciclovir—Dyspnoea—Epirubicin—thyroid cancer	0.000989	0.00113	CcSEcCtD
Valaciclovir—Somnolence—Epirubicin—thyroid cancer	0.000986	0.00113	CcSEcCtD
Valaciclovir—Anorexia—Doxorubicin—thyroid cancer	0.000978	0.00112	CcSEcCtD
Valaciclovir—Dyspepsia—Epirubicin—thyroid cancer	0.000976	0.00112	CcSEcCtD
Valaciclovir—SLC6A14—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000964	0.00753	CbGpPWpGaD
Valaciclovir—Decreased appetite—Epirubicin—thyroid cancer	0.000964	0.00111	CcSEcCtD
Valaciclovir—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000958	0.0011	CcSEcCtD
Valaciclovir—Fatigue—Epirubicin—thyroid cancer	0.000956	0.0011	CcSEcCtD
Valaciclovir—Constipation—Epirubicin—thyroid cancer	0.000949	0.00109	CcSEcCtD
Valaciclovir—Pain—Epirubicin—thyroid cancer	0.000949	0.00109	CcSEcCtD
Valaciclovir—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000935	0.00107	CcSEcCtD
Valaciclovir—SLC10A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000932	0.00727	CbGpPWpGaD
Valaciclovir—Insomnia—Doxorubicin—thyroid cancer	0.000928	0.00106	CcSEcCtD
Valaciclovir—Paraesthesia—Doxorubicin—thyroid cancer	0.000922	0.00106	CcSEcCtD
Valaciclovir—Dyspnoea—Doxorubicin—thyroid cancer	0.000915	0.00105	CcSEcCtD
Valaciclovir—Feeling abnormal—Epirubicin—thyroid cancer	0.000914	0.00105	CcSEcCtD
Valaciclovir—Somnolence—Doxorubicin—thyroid cancer	0.000912	0.00105	CcSEcCtD
Valaciclovir—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000907	0.00104	CcSEcCtD
Valaciclovir—Dyspepsia—Doxorubicin—thyroid cancer	0.000903	0.00104	CcSEcCtD
Valaciclovir—SLC15A2—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000897	0.00701	CbGpPWpGaD
Valaciclovir—Decreased appetite—Doxorubicin—thyroid cancer	0.000892	0.00102	CcSEcCtD
Valaciclovir—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000886	0.00102	CcSEcCtD
Valaciclovir—SLC10A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000886	0.00691	CbGpPWpGaD
Valaciclovir—Fatigue—Doxorubicin—thyroid cancer	0.000885	0.00101	CcSEcCtD
Valaciclovir—Urticaria—Epirubicin—thyroid cancer	0.000881	0.00101	CcSEcCtD
Valaciclovir—Constipation—Doxorubicin—thyroid cancer	0.000878	0.00101	CcSEcCtD
Valaciclovir—Pain—Doxorubicin—thyroid cancer	0.000878	0.00101	CcSEcCtD
Valaciclovir—Body temperature increased—Epirubicin—thyroid cancer	0.000877	0.00101	CcSEcCtD
Valaciclovir—Abdominal pain—Epirubicin—thyroid cancer	0.000877	0.00101	CcSEcCtD
Valaciclovir—Feeling abnormal—Doxorubicin—thyroid cancer	0.000846	0.00097	CcSEcCtD
Valaciclovir—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000839	0.000963	CcSEcCtD
Valaciclovir—SLC15A1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000833	0.0065	CbGpPWpGaD
Valaciclovir—SLC22A6—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.000826	0.00645	CbGpPWpGaD
Valaciclovir—SLC22A6—SLC-mediated transmembrane transport—CP—thyroid cancer	0.000826	0.00645	CbGpPWpGaD
Valaciclovir—Hypersensitivity—Epirubicin—thyroid cancer	0.000817	0.000937	CcSEcCtD
Valaciclovir—Urticaria—Doxorubicin—thyroid cancer	0.000815	0.000935	CcSEcCtD
Valaciclovir—Body temperature increased—Doxorubicin—thyroid cancer	0.000811	0.00093	CcSEcCtD
Valaciclovir—Abdominal pain—Doxorubicin—thyroid cancer	0.000811	0.00093	CcSEcCtD
Valaciclovir—SLC6A14—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.00081	0.00632	CbGpPWpGaD
Valaciclovir—Asthenia—Epirubicin—thyroid cancer	0.000796	0.000913	CcSEcCtD
Valaciclovir—Pruritus—Epirubicin—thyroid cancer	0.000785	0.0009	CcSEcCtD
Valaciclovir—Diarrhoea—Epirubicin—thyroid cancer	0.000759	0.00087	CcSEcCtD
Valaciclovir—Hypersensitivity—Doxorubicin—thyroid cancer	0.000756	0.000867	CcSEcCtD
Valaciclovir—SLC22A8—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000741	0.00578	CbGpPWpGaD
Valaciclovir—Asthenia—Doxorubicin—thyroid cancer	0.000736	0.000845	CcSEcCtD
Valaciclovir—Dizziness—Epirubicin—thyroid cancer	0.000733	0.000841	CcSEcCtD
Valaciclovir—Pruritus—Doxorubicin—thyroid cancer	0.000726	0.000833	CcSEcCtD
Valaciclovir—Vomiting—Epirubicin—thyroid cancer	0.000705	0.000809	CcSEcCtD
Valaciclovir—Diarrhoea—Doxorubicin—thyroid cancer	0.000702	0.000805	CcSEcCtD
Valaciclovir—Rash—Epirubicin—thyroid cancer	0.000699	0.000802	CcSEcCtD
Valaciclovir—Dermatitis—Epirubicin—thyroid cancer	0.000699	0.000801	CcSEcCtD
Valaciclovir—Headache—Epirubicin—thyroid cancer	0.000695	0.000797	CcSEcCtD
Valaciclovir—Dizziness—Doxorubicin—thyroid cancer	0.000679	0.000778	CcSEcCtD
Valaciclovir—SLC10A2—Metabolism—TPR—thyroid cancer	0.00066	0.00515	CbGpPWpGaD
Valaciclovir—Nausea—Epirubicin—thyroid cancer	0.000659	0.000756	CcSEcCtD
Valaciclovir—Vomiting—Doxorubicin—thyroid cancer	0.000653	0.000748	CcSEcCtD
Valaciclovir—SLC10A2—Metabolism—PRKAR1A—thyroid cancer	0.000649	0.00507	CbGpPWpGaD
Valaciclovir—Rash—Doxorubicin—thyroid cancer	0.000647	0.000742	CcSEcCtD
Valaciclovir—Dermatitis—Doxorubicin—thyroid cancer	0.000646	0.000741	CcSEcCtD
Valaciclovir—Headache—Doxorubicin—thyroid cancer	0.000643	0.000737	CcSEcCtD
Valaciclovir—SLC22A6—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.000618	0.00483	CbGpPWpGaD
Valaciclovir—Nausea—Doxorubicin—thyroid cancer	0.00061	0.000699	CcSEcCtD
Valaciclovir—SLC15A2—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000609	0.00476	CbGpPWpGaD
Valaciclovir—SLC15A2—Transmembrane transport of small molecules—CP—thyroid cancer	0.000609	0.00476	CbGpPWpGaD
Valaciclovir—SLC15A2—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000599	0.00468	CbGpPWpGaD
Valaciclovir—SLC10A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000588	0.00459	CbGpPWpGaD
Valaciclovir—SLC15A1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000565	0.00441	CbGpPWpGaD
Valaciclovir—SLC15A1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000565	0.00441	CbGpPWpGaD
Valaciclovir—SLC15A1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000556	0.00434	CbGpPWpGaD
Valaciclovir—SLC22A8—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000503	0.00393	CbGpPWpGaD
Valaciclovir—SLC22A8—Transmembrane transport of small molecules—CP—thyroid cancer	0.000503	0.00393	CbGpPWpGaD
Valaciclovir—SLC22A8—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000495	0.00386	CbGpPWpGaD
Valaciclovir—SLC10A2—Metabolism—SLC5A5—thyroid cancer	0.000494	0.00385	CbGpPWpGaD
Valaciclovir—SLC10A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000463	0.00361	CbGpPWpGaD
Valaciclovir—SLC15A2—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000456	0.00356	CbGpPWpGaD
Valaciclovir—SLC15A1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000423	0.0033	CbGpPWpGaD
Valaciclovir—SLC22A6—Transmembrane transport of small molecules—CP—thyroid cancer	0.00042	0.00328	CbGpPWpGaD
Valaciclovir—SLC22A6—Transmembrane transport of small molecules—TPR—thyroid cancer	0.00042	0.00328	CbGpPWpGaD
Valaciclovir—SLC10A2—Metabolism—RXRA—thyroid cancer	0.000415	0.00324	CbGpPWpGaD
Valaciclovir—SLC22A6—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000413	0.00322	CbGpPWpGaD
Valaciclovir—SLC10A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.000404	0.00315	CbGpPWpGaD
Valaciclovir—SLC15A2—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000383	0.00299	CbGpPWpGaD
Valaciclovir—SLC22A8—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000376	0.00294	CbGpPWpGaD
Valaciclovir—SLC15A1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000356	0.00278	CbGpPWpGaD
Valaciclovir—SLC22A8—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000316	0.00247	CbGpPWpGaD
Valaciclovir—SLC22A6—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000314	0.00245	CbGpPWpGaD
Valaciclovir—SLC22A6—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000264	0.00206	CbGpPWpGaD
Valaciclovir—SLC10A2—Metabolism—PPARG—thyroid cancer	0.000262	0.00204	CbGpPWpGaD
Valaciclovir—SLC10A2—Metabolism—PTGS2—thyroid cancer	0.000206	0.00161	CbGpPWpGaD
Valaciclovir—SLC10A2—Metabolism—PTEN—thyroid cancer	0.00018	0.0014	CbGpPWpGaD
Valaciclovir—SLC10A2—Metabolism—AKT1—thyroid cancer	0.000104	0.000808	CbGpPWpGaD
